These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34703536)

  • 1. Unravelling the effect of the E545K mutation on PI3Kα kinase.
    Galdadas I; Gervasio FL; Cournia Z
    Chem Sci; 2020 Apr; 11(13):3511-3515. PubMed ID: 34703536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
    Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
    Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free energy landscape of the PI3Kα C-terminal activation.
    Kotzampasi DM; Papadourakis M; Burke JE; Cournia Z
    Comput Struct Biotechnol J; 2024 Dec; 23():3118-3131. PubMed ID: 39229338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.
    Layton MJ; Rynkiewicz NK; Ivetac I; Horan KA; Mitchell CA; Phillips WA
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
    Kong D; Yamori T; Yamazaki K; Dan S
    Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
    Gkeka P; Papafotika A; Christoforidis S; Cournia Z
    J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
    Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
    Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
    Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
    Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
    Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
    Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of PI3Kα activation at the atomic level.
    Zhang M; Jang H; Nussinov R
    Chem Sci; 2019 Mar; 10(12):3671-3680. PubMed ID: 30996962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
    Ghalamkari S; Alavi S; Mianesaz H; Khosravian F; Bahreini A; Salehi M
    Life Sci; 2021 Mar; 269():118759. PubMed ID: 33189828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Dynamics Simulations to Investigate the Binding Mode of the Natural Product Liphagal with Phosphoinositide 3-Kinase α.
    Gao Y; Ma Y; Yang G; Li Y
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27367663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
    Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
    Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
    Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
    J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
    Layton MJ; Saad M; Church NL; Pearson RB; Mitchell CA; Phillips WA
    BMC Biochem; 2012 Dec; 13():30. PubMed ID: 23270540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.